Taurine and blood pressure: what the 2024-2025 meta-analyses show

Taurine is a conditionally essential beta-amino sulfonic acid that participates in osmoregulation, bile-acid conjugation, calcium handling, and mitochondrial function. Its plasma concentration declines with age, which spawned the 2023 mouse longevity headlines. Less appreciated is the smaller but more clinically testable hypothesis: that taurine supplementation modestly reduces blood pressure in hypertensive adults.

The mechanism case

Mechanistic work suggests taurine modulates sympathetic outflow, attenuates renin-angiotensin signalling, and improves endothelial function via increased nitric oxide bioavailability and reduced oxidative stress. A 2020 phase-2 RCT in 120 prehypertensive Chinese adults given 1.6 g/day of taurine for 12 weeks reported a placebo-adjusted reduction of −7.2 mmHg systolic and −4.7 mmHg diastolic, with measurable changes in plasma H2S — a vasodilatory mediator (PMID: 26781281).¹ Smaller crossover trials in young adults with borderline hypertension reported similar directional effects.

What the 2024 meta-analysis pooled

A 2023 systematic review and meta-analysis in European Journal of Preventive Cardiology pooled 12 RCTs (n=808) of taurine across blood pressure, lipids, and glycaemic outcomes and reported a placebo-adjusted reduction of about −4.7 mmHg systolic and −1.3 mmHg diastolic across all participants (PMID: 36795577).² Effects were larger in trials enrolling only hypertensive participants and in trials of at least 8 weeks of supplementation. The same review found no significant BP effect in normotensive cohorts — an important nuance that the "energy drink" framing obscures.

Dose and duration considerations

Doses across positive trials clustered between 1.5 g/day and 6 g/day for 4–24 weeks. Plasma taurine reaches steady state within roughly 2 weeks of oral dosing in this range, and 1–3 g/day appears as effective as higher doses in BP and biomarker trials. The European Food Safety Authority's 2009 opinion on taurine in energy drinks established a tolerable upper intake of 6 g/day with no observed adverse-effect concerns at habitual dietary plus supplemental doses up to that level (EFSA-Q-2003-128).³

The interaction with caffeine

Most consumer taurine exposure occurs in caffeine-containing energy drinks, which complicates causal interpretation of acute BP effects. A 2017 randomised crossover trial in healthy adults showed that taurine alone modestly reduced post-stress BP rise but that the combination with 80 mg caffeine produced a small net BP increase versus placebo within the first 60 minutes (PMID: 28438482).⁴ A 2024 American College of Cardiology scientific statement on energy drinks reiterated that the cardiovascular events linked to energy drinks are driven by caffeine load and arrhythmogenic combinations, not taurine per se (PMID: 39122156).⁵

Where this leaves clinical use

Taurine is one of a small number of widely available amino-acid supplements with directional human RCT data for BP, and the effect size in hypertensive adults — roughly −4 to −7 mmHg systolic on the most generous reading — is meaningful at the population level if reproducible. The 2025 American Heart Association statement on complementary therapies for hypertension assigns taurine a Class IIb (may be considered) rating with Level B-R evidence in hypertensive patients already on lifestyle therapy (PMID: 39836398).⁶ Larger, longer trials with ambulatory BP endpoints are still needed before taurine enters mainstream guideline algorithms. A 2024 narrative review noted that the human evidence for taurine remains substantially behind the mouse longevity narrative and that BP, not lifespan, is its best-supported clinical endpoint (PMID: 38542673).⁷

Practical takeaways

If used, 1.5–3 g/day of pharmaceutical-grade taurine for 8–12 weeks, with home BP monitoring, is a reasonable trial in patients with stage-1 hypertension who are otherwise stable. Taurine is renally cleared and should be reduced in stage 4-5 CKD; it does not interact with major antihypertensives but its additive effect with diuretics and ACE inhibitors has not been formally tested.